We Aim to Examine the Predictors of Sustained Complete Renal Remission in Patients With Lupus Nephritis at Sohag University Hospital
Conditions
Brief summary
Systemic lupus erythematosus (SLE) is an autoimmune disease which may give rise to multiple organ involvement because of immune complex deposits. Lupus nephritis (LN) is one of the severe manifestations of systemic lupus erythematous (SLE) and a common cause for end-stage renal disease, significantly affecting the survival of SLE patients Immunosuppressive treatment is the major therapy for active LN. Generally, at least six months are needed to assess treatment responses Failure to respond to immunosuppressive therapy can lead to a worsening of renal function
Detailed description
This study will be prospectively analyzing the clinical data of LN patients who received standard immunosuppressive therapy and were regularly followed up at our center for more than six months. These patients will not change treatment regimen during the six months. As remission is an independent predictor of good long term prognosis in lupus nephritis. We aim to examine the predictors of sustained complete renal remission in patients with lupus nephritis at Sohag University Hospital and to analyze data of lupus nephritis patients to find parameters that can predict remission and improve outcome of our cases
Interventions
follow up for treatment response
Sponsors
Study design
Eligibility
Inclusion criteria
* o Patients diagnosed with LN at Sohag University Hospital * Patients in regular follow-up for more than six months after immunosuppressive therapy * Baseline urinary protein/creatinine ratio (UPCR) more than 1 g/g * Baseline C3 less than 55 mg/ dl * No change in immunosuppressive therapy within six months
Exclusion criteria
* o Patients with incomplete pathological data and the number of glomeruli being \<10 per biopsy specimen * Age \<14 years old End-stage renal disease (ESRD) status on admission (sustained estimated glomerular filtration rate (eGFR) \<15 ml/min per 1.73m2) * Patients with advanced comorbid conditions like advanced liver cirrhosis or heart failure or malignancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| complete renal response | 6 months | Alb \_35 g/l, UPCR\<0.3 g/g, a normal range of sCr or at a level increasing no more than 15% from baseline and without lupus flares. |
Countries
Egypt